Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Capsaicin - Centrexion Therapeutics

Drug Profile

Capsaicin - Centrexion Therapeutics

Alternative Names: Adlea; ALGRX-4975; CNTX-4975; CNTX-4975-05; trans-capsaicin; VLNX-4975

Latest Information Update: 18 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Johns Hopkins University
  • Developer Anesiva; Centrexion Therapeutics
  • Class Antipruritics; Catechols; Local anaesthetics; Monounsaturated fatty acids; Non-opioid analgesics; Polyunsaturated alkamides; Small molecules
  • Mechanism of Action GABA A receptor modulators; Melatonin receptor modulators; Substance P inhibitors; TRPV1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuropathic pain
  • New Molecular Entity No

Highest Development Phases

  • Phase III Pain
  • Phase II Neuropathic pain
  • Discontinued Postoperative pain

Most Recent Events

  • 17 Sep 2019 Centrexion Therapeutics completes enrollment in the phase III VICTORY-3 trial in Pain (In adults, In the elderly)in USA (Intra-articular) (NCT03661996)
  • 18 Jul 2019 Interim efficacy and safety data from the phase-III VICTORY-3 trial in Pain associated with osteoarthritis released by Centrexion Therapeutics Corporation
  • 12 Jun 2019 Efficacy data from the phase-III VICTORY-3 trial in Pain associated with osteoarthritis presented at the 20th Annual Congress of the European League Against Rheumatism (EULAR-2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top